TELA Bio, Inc. (TELA)

Market Cap	109.71M
Revenue (ttm)	58.45M
Net Income (ttm)	-46.66M
Shares Out	24.65M
EPS (ttm)	-2.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	84,521
Open	4.450
Previous Close	4.470
Day's Range	4.340 - 4.525
52-Week Range	4.235 - 11.260
Beta	0.95
Analysts	Strong Buy
Price Target	13.67 (+207.19%)
Earnings Date	May 9, 2024

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 8, 2019
• Employees: 227
• Stock Exchange: NASDAQ
• Ticker Symbol: TELA

Financial Performance

In 2023, TELA Bio's revenue was $58.45 million, an increase of 41.13% compared to the previous year's $41.42 million. Losses were -$46.66 million, 5.35% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for TELA stock is "Strong Buy." The 12-month stock price forecast is $13.67, which is an increase of 207.19% from the latest price.

Price Target

$13.67

(207.19% upside)

Analyst Consensus: Strong Buy